A Randomized Phase 3 Study of Tasisulam Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle vs. Paclitaxel as Second-Line Treatment in Patients with Metastatic Melanoma

Mise à jour : Il y a 5 ans
Référence : EUCTR2009-014591-21

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective of this study is to compare the overall survival (OS) of patients who have received one prior regimen of dacarbazine or temozolomide-based chemotherapy for metastatic malignant melanoma when treated with either tasisulam or paclitaxel.


Critère d'inclusion

  • Second Line metastatic melanoma